Incredible opportunity and experience to attend #ISDE2026 in Kyoto, Japan. Highlighted how our organ-on-a-chip model stands out as an excellent predictive tool for therapy response in Esophageal adenocarcinoma. #NAMs #Organoids #PrecisionOncology #OrganOnChip

Placing PEG tubes among patients with resectable GEJ and esophageal cancer risks injuring the gastroepiploic vessels and can't use the stomach as a conduit! @ASGEendoscopy @ForegutSociety @AmCollegeGastro @SSATNews @SAGES_Updates @SocSurgOnc @STS_CTsurgery

A new editorial argues for ending the madness of flawed retrospective studies comparing Surgery vs SBRT for stage I NSCLC. lungcancerjournal.info/artic…

KRAS G12D - long considered “undruggable.” Now we finally have real clinical signal. Concurrent @nejm publication in #elcc26 Setidegrasib (ASP3082), a KRAS G12D degrader, shows promising activity in heavily pretreated NSCLC. 🧪 Population 2L+ KRAS G12D NSCLC Most had prior chemo + IO 💉 Results (600 mg weekly) ORR: 36% mPFS: 8.3 mo 2L/3L subgroup → ORR 38%, mPFS 11.2 mo ⚠️ Safety Infusion reactions common (80%) but manageable Grade ≥3 TRAEs: 9% 🎯 Takeaway First meaningful signal in KRAS G12D NSCLC Not practice-changing yet But clearly practice-watching 🔬 📖 Full paper in comment ⬇️ #LungCancer #NSCLC #KRAS @OncoAlert @myesmo @esmo_open @ASCO

Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma ➡️ doi.org/10.1093/bjs/znag012 📊 Individual patient data from 7 phase III RCTs (n=1,044 ESCC patients, 6 countries) 💊 NAC vs 🔥 NACRT → pCR rates: 6.9% vs 34.2% 🔎 Among patients achieving pCR (n=192):  • 5-year OS: 97.5% (NAC) vs 70.4% (NACRT)  • 5-year RFS: 80.8% (NAC) vs 63.7% (NACRT) 📈 Multivariable analysis confirmed a significant survival advantage for NAC in the pCR subgroup 🎯 Take-home: pCR is not biologically equivalent across modalities. ESCC patients achieving pCR after NAC have an exceptionally favourable prognosis—raising the question of whether this group could be considered for future surgery-avoidance or watch-and-wait strategies. Work by Jun Okui , Satoru Matsuda , Kengo Nagashima , Yasunori Sato , Hirofumi Kawakubo , Thomas Ruhstaller , Peter Thuss-Patience , Magnus Nilsson , Fredrik Klevebro , Lijie Tan , Shaoyuan Zhang , Thomas Aparicio , Guillaume Piessen , Charlène van der Zijden , Bianca Mostert , Bas P L Wijnhoven , Takahiro Tsushima , Hiroya Takeuchi , Ken Kato , Yuko Kitagawa #SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide #some4UGI #uppergi #esophagealcancer #gastriccancer #reflux @ISDE_net @Augishealth @roux_group @T4UGIS @SARONG_Trial @YoungIFSO #bariatricsurgery

REBOA = higher mortality (47% vs 36%), more transfusions, longer time to OR. No survival benefit. Check the new study by Hatchimonji et al. bit.ly/441iuXH and Jansen's commentary bit.ly/48a2TYi. @jhatchmd @dianehaddadmd @pdowzicky @markseamonmd

So incredibly proud of @MHShahzad5 @ronirayes and @JonathanCools for getting this awesome review. The sum of so much work on Neutrophil Extracellular Trap biology in cancer and some insights on how we may transition to the therapeutic space, now 15 years since we first conceived that NETs might play a role in cancer progression! nature.com/articles/s41568-0…